INTRODUCTION
Bile acids are physiological detergents that facilitate absorption, transport and distribution of lipid-soluble fats and vitamins, and excretion of lipids and cholesterol. However, hydrophobic bile acids are inherently cytotoxic and their formation and elimination must be tightly regulated. This homeostasis is provided by two general pathways: (i) feed-forward regulation, where toxic bile acids trigger an adaptive protective response, that results in an increase in expression of a range of genes responsible for bile acid detoxification and/or excretion and; (ii) feedback regulation, where accumulating bile acids cause reduced transcription of genes such as cholesterol 7α-hydroxylase (CYP7A1), the rate limiting step in bile acid formation by the 'classic' pathway of bile acid synthesis (1) . While the mechanisms of feedback regulation are now relatively well understood, the processes involved in feed-forward regulation are less clear.
CYP3A enzymes are predominantly expressed in the liver and small intestinal mucosa and catalyse the metabolic conversion of a wide diversity of xenobiotics and endogenous substrates to more polar derivatives. These enzymes exhibit adaptive transcriptional regulation in response to a range of xenobiotic inducing chemicals, which include some therapeutic drugs. Cytochrome P450 3A4 (CYP3A4) is active in the hydroxylation of bile acids and steroid hormones (2, 3) . This is significant because the relative cytotoxicity of each bile acid is attributable to its hydrophobicity, and both ring hydroxylations and conjugation reduce hydrophobicity and effectively detoxify bile acids as well as rendering them accessible to excretory transporters (4) . Bile acid-mediated induction of CYP3A enzymes therefore represents an important potential feed-forward mechanism for bile acid homeostasis.
There is indirect evidence that CYP3A induction occurs in response to cholestasis. Increased excretion of the 6α-hydroxylated bile acids, α-hyocholic acid (α-HCA) and hyodeoxycholic acid (HDCA), occurs in cholestatic patients and in women with cholestasis of pregnancy (5-7). In rats, concentrations of the 6β-hydroxylated bile acid, β-muricholic acid (β-MCA) increase after bile duct ligation (BDL) (8, 9) . Moreover, while hepatic CYP concentrations are generally decreased in human livers with biliary cirrhosis secondary to chronic cholestatic liver diseases, CYP3A4 expression is relatively preserved (10) , suggesting that CYP3A induction occurs as a defensive response to bile acid accumulation, even in advanced disease.
Adaptive regulation of CYP3A4 is now known to be mediated by members of the nuclear receptor superfamily that function as ligand-activated transcription factors. Specifically, the pregnane X receptor (PXR; NR1I2) (3, (11) (12) (13) (14) , constitutive androstane receptor (CAR; NR1I3) (15) , and 1,25-dihydroxyvitamin D receptor (VDR; NR1I1) (16) have been implicated as important 'sensors' for potentially toxic compounds that can impact on CYP3A expression. These receptors heterodimerize with the receptor for 9-cis retinoic acid-α (RXRα ; NR2B1) and recognise a range of small lipophilic molecules that includes endobiotic (endogenously synthesised) and xenobiotic compounds.
Recently, PXR has been shown to be a low affinity receptor for lithocholic acid (LCA) and its metabolite, 3-keto-lithocholic acid (3-keto-LCA) (3, 11, 17) . In studies of knockout and transgenic animals, activation of PXR can both induce CYP3A enzymes and confer resistance to toxicity by LCA (3, 11) . It has therefore been suggested that LCA represents the endogenous PXR ligand, and that PXRmediated gene induction may be the predominant pathway of feed-forward regulation of bile acid detoxification and elimination (3, 11, 18) . However concentrations of LCA and other bile acids have not been measured in conjunction with an assessment of CYP3A induction in in vivo models of cholestasis.
In the present study, we have utilized a recently described transgenic mouse model incorporating a regulatory human CYP3A4 transgene (19) to explore the in vivo relationship between specific bile acids and physiological adaptive CYP3A gene regulation in acute cholestasis induced by surgical BDL. We provide evidence that adaptive up-regulation of both endogenous mouse and introduced human CYP3A genes does occur in response to bile acid accumulation, and that this response is not dependent on increases in circulating LCA. using automated procedures. Serum and urine samples were also frozen at -70C for subsequent bile acid analysis. Liver and duodenal tissues were collected for staining with 5-bromo-4-chloro-3-indolyl-β-Dgalactopyranoside (X-gal), and liver was snap frozen in liquid nitrogen for quantitative β-galactosidase assessment, protein analysis, mRNA extraction and bile acid analysis. Liver samples were also embedded in OCT compound for β-galactosidase staining of frozen sections.
Bile Acid Administration. Mice were administered lithocholic acid, 0.125mg/g body weight in 100µL corn oil or vehicle alone twice daily by intraperitoneal (i.p.) injection for 7 days. Mice were sacrificed by exsanguination 12 hours after the last injection.
Assessment of Liver Histology. Consecutive sections of liver (4µm thick) from paraffinembedded liver were cut for haematoxylin and eosin staining for evaluation of liver injury and necrosis.
Analysis of CYP3A4 Transgene Expression β-Galactosidase activity was visualised in slices
and frozen sections of liver and other tissues following staining with X-gal. Tissues were fixed in 0.25% glutaraldehyde, 0.1M phosphate buffer pH7.3, 5mM EGTA, 2 mM MgCl 2 : washed in 0.1M phosphate buffer, pH 7.3, 0.01% sodium deoxycholate, 0.025% Nonidet P40, and 2mM MgCl 2 ; and stained by incubation at 37C in wash solution supplemented with 1mg/ml X-gal, 5mM potassium ferricyanide, and 5mM potassium ferrocyanide. Tissue slices were examined under a stereomicroscope (magnification, 20X) and tissue sections using a conventional microscope (magnification, 100X). The extent of β-galactosidase activity was quantitated in whole liver homogenates (100mg fresh tissue/ml 0.25M TrisHCl, pH 7.3) using the O-nitrophenyl-β-D-galactopyranoside (ONPG) assay as described previously (20) . After appropriate dilution, the homogenate was incubated with β-galactosidase assay reagent (0.1M sodium phosphate buffer, pH7.3, 1mM MgCl 2 , 50 mM β-mercaptoethanol, and 0.88mg/ml ONPG) at 37C, quenched by the addition of 1M Na 2 CO 3 , and the absorbance at 420nm was determined. Protein concentration was quantified in the same whole liver homogenates using a commercially available kit (DC Protein Assay; Bio-Rad, Hercules, CA), and the units of β-galactosidase activity are given as A 420 /mg protein/minute. The probe was designed to cross an intron-exon junction to avoid interference from genomic DNA.
Additionally, primer and probe sequences were chosen to avoid detection of other Cyp3a subfamily members. Results were normalized against GAPDH, determined using the following primers and Cycle parameters for all PCR were: 50C for 2 min then 95C for 10 min, followed by 40 cycles of 95C for 15 sec and 60C for 1 min.
Quantitation of Bile Acids by High Performance Liquid Chromatography / Mass
Spectrometry. Serum or urine (100uL) was diluted with 100uL of PBS to which 41ng of deuterated assay internal standard (cholic acid) was added. Solid phase extraction was carried out using Oasis HLB voltage 5V, RF lens 0.3V. Source temperature was 100C and desolvation temperature was 300C.
Desolvation gas flow was set at 350L/Hr and cone gas flow rate was 60L/Hr. The limit of quantitation was 40nmol/L for individual bile acids.
Statistical Analysis. Treatment groups were compared using factorial ANOVA, and post-hoc analysis was performed using the Bonferroni/Dunn test for parametric data. These results are presented as mean ± S.D. Data from bile acid analysis were non-parametric, and treatment groups were compared
RESULTS

Liver Weight and Assessment of Liver Injury and Cholestasis after BDL. CYP3A4/lacZ
transgenic male mice were subjected to BDL or sham operation, and sacrificed after 3, 6 and 10 days.
Liver weight progressively increased after BDL, with a two-fold increase in BDL animals compared with shams at day 10 (mean 2.5 ± 0.3g vs. 1.2 ± 0.01g; p<0.001). Serum bilirubin and ALT were abnormal in BDL animals at all timepoints, confirming both cholestasis and liver injury. There was a progressive increase in serum ALT to a mean of 1,607 ± 394 U/L 10 days after BDL (Fig. 1A) , and serum bilirubin peaked 6 days after BDL with mean of 137 ± 100µmol/L (Fig. 1B) . At all timepoints, ALT and bilirubin were significantly greater in BDL animals compared with shams (p<0.001). (19) . When intestinal epithelium was examined, no significant difference in transgene expression was seen between BDL and sham animals, although the transgene was inducible in the gut following dexamethasone administration (not shown). This lack of intestinal transgene induction after BDL may be due to the effect of bile acid diversion from the gut.
CYP3A4 Transgene Expression In
Quantitative Expression of CYP3A4/lacZ Transgene and Endogenous Mouse Cyp3a11 after
BDL. CYP3A4/lacZ transgene expression was quantified by measuring β-galactosidase activity in whole liver homogenates using the ONPG assay. Transgene expression increased significantly from day 6 in BDL animals compared with shams, to a mean 80-fold increase in induction on day 10 ( Fig. 4A) . On univariate analysis of variance, a statistically significant interaction was found between the effects of the procedure (BDL) and time. There was a linear increase in ONPG at a rate of 0.43/day (SE=0.007, p<0.001) in the BDL group. The sham group remained unchanged over time (slope=-0.002, SE=0.008,
p=0.8).
Cyp3a11 is an endogenous mouse Cyp3a gene and is the likely homologue of CYP3A4, and relative expression was determined using real-time quantitative RT-PCR analysis. A significant increase in Cyp3a11 expression was demonstrated both 6 (3.7-fold) and 10 days after BDL (Fig. 4B ), in keeping with the physiological relevance of the CYP3A4/lacZ transgene induction.
Changes to Serum Bile Acid Concentrations after BDL. Individual serum bile acid concentrations were determined in BDL and sham mice at different timepoints using LC/MS (Table I) .
Concentrations of β-MCA, a 6β-hydroxylated bile acid, and its tauro conjugate were massively elevated in BDL animals compared with sham animals at all three timepoints, and α-MCA was also elevated on day 3. Additionally, an ion consistent with taurine-conjugated unsaturated trihydroxy-bile acids (m/z 512), believed to correspond to tauro-∆ 22 -muricholate isomers (21) was also approximately 40-fold greater than that of unconjugated β-MCA in BDL animals compared with shams (data not shown).
The tauro-conjugate of the major murine primary bile acid, CA, was significantly increased at all timepoints after BDL, although changes in serum concentration of unconjugated CA and glycocholic acid (GCA) did not reach statistical significance. This greater magnitude of increase in TCA is consistent with the known preference of rodents to amidate with taurine as the major metabolic pathway for conjugation (22) . Likewise, serum concentrations of taurochenodeoxycholic acid (TCDCA) were substantially increased after BDL, but there was no significant increase in unconjugated chenodeoxycholic acid (CDCA) or glycochenodeoxycholic acid (GCDCA). As expected, concentrations of secondary bile acids including LCA, deoxycholic acid (DCA) and HDCA did not increase after BDL, reflecting the interruption of passage of bile acids into the gut and lack of exposure to intestinal bacteria.
Hepatic and Urine Bile Acid Concentrations after BDL.
The bile acid concentrations in liver are presented in Table II , and concentrations in urine are presented in Table III . The patttern of changes in both liver and urine is generally similar to that in serum, refelcting the massive increase in tauro conjugates and β-hydroxylated metabolites of the primary bile acids. In particular, significant increases in conjugates of CA, CDCA,UDCA and β-MCA, and increases in α-MCA were noted in urine and livers of BDL animals. In liver, the tauro conjugate of UDCA was also specifically identified and shown to be (Table IV) .
MDCA, a 6β-hydroxylated metabolite of LCA was also increased; however α-MCA and β-MCA were not significantly elevated. (3), and 6α-hydroxylation of T-CDCA (7). CYP3As are also active catalysts of steroid hormone 6β-hydroxylation (2), and there is a strong correlation between 6α-hydroxylation of LCA, CYP3A levels and testosterone 6β-hydroxylation (7). In hamsters, CYP3A10 encodes a lithocholic acid 6β-hydroxylase (23) . Additionally, in humans, CYP3A4 is the predominant enzyme responsible for 25-and 26-hydroxylations of 5β-cholestane-3α 7α12α-triol and 27-hydroxylation of 5β-cholestane-3α 7α12α,25-tetrol in the classic bile acid biosynthetic pathway (24, 25) . In mice, Cyp3a11 is responsible for these microsomal side chain hydroxylations (25) .
In healthy adult humans, bile acid hydroxylation represents a relatively minor pathway for bile acid elimination, and 6α-hydroxylated bile acids are only found in small amounts in bile, serum and urine (7) . However, in the presence of cholestasis, urinary concentrations of α-HCA and HDCA, the 6α-hydroxylated metabolites of CDCA and LCA, increase (5,7). 6α-hydroxylation is followed by 6-0-glucuronidation and excretion, and this pathway is believed to be important for the detoxification of these hydrophobic bile acids (26) . In the present study, concentrations of α-HCA and HDCA were not increased after BDL, but this is expected as rodents preferentially 6β-hydroxylate bile acids (26) (27) (28) (29) .
Additionally, in rats HDCA is predominantly a secondary bile acid, derived from β-MCA through 7β-dehydroxylation and 6β-hydroxy-epimerization (30) .
We have now shown that the 6β-hydroxylated bile acids, α-MCA, and especially β-MCA increase significantly after BDL in mice. These 6β-hydroxylated products of CDCA are relatively hydrophilic allowing subsequent excretion in the urine (31). Similar results have been found in BDL rats with increases in β-MCA (8,9,32) and bile acid 6β-hydroxylase activity (27, 29) . The enzyme responsible for 6β-hydroxylation of CDCA and LCA in mice has not been characterised; however Cyp3a11 is known to be active in hepatic microsomal testosterone 6β-hydroxylation (33) , an activity that is widely accepted as a marker for the CYP3A subfamily enzymes, and CDCA 6β-hydroxylation is inducible by dexamethasone, a known inducer of Cyp3a11 (34) . It therefore seems likely that the hepatic Cyp3a11 induction that we have demonstrated mediates the increase in bile acid 6β-hydroxylation. However, recent work has demonstrated an increase in Cyp3a11 in LCA-fed, FXR-null mice, associated with a decrease in LCA 6β-hydroxylation, an increase in LCA 6α-hydroxylation and an increase in testosterone 6β-hydroxylation (35) . This suggests that in mice, several enzymes may mediate stereospecific hydroxylase reactions of different bile acid and steroid substrates. Interestingly, in the present study BDL was associated with significantly higher concentrations of β-hydroxylated bile acids and greater Cyp3a11 induction than LCA administration. The increase in β-MCA was seen from day 3 after BDL, prior to the significant increase in Cyp3a11 expression. This is consistent with previous work in rats suggesting that an additional pathway may contribute to 6β-hydroxylation of bile acids in biliary obstruction (9) . An important aspect of the present study is the ability to study the response of a regulatory human CYP3A4 transgene to cholestasis. Our work confirms the earlier indirect evidence from human studies suggesting that CYP3A up regulation is an important early protective response to cholestasis, and is associated with an increase in bile acid hydroxylation.
Changes in individual serum and urine bile acids after BDL have not previously been described in mice, presumably due to difficulties in analysing the small volume samples obtainable. Using a highly efficient and sensitive LC/MS-based method, we have found an increase in conjugated CA, a dominant primary bile acid in normal rodent bile. This is consistent with previous studies in the rat (32) , although an early transient increase in unconjugated CA has also been observed (36) . The more hydrophobic primary bile acid, CDCA is usually of negligible quantitative importance in healthy rats, but has been reported to increase in serum (8, 37) and bile (36) after BDL, and we have demonstrated a significant increase in TCDCA in serum, liver and urine of mice following the BDL procedure. Additionally, we have demonstrated a significant increase in TUDCA after BDL.
In the present study there was no accumulation of LCA or its conjugates after BDL. This was expected in the BDL model of cholestasis, which interrupts the normal flow of bile acids into the gut, as LCA is a secondary bile acid formed by 7-dehydroxylation of CDCA by intestinal bacteria. This raises the question of the exact mechanism for CYP3A induction in cholestasis. Previous investigators have proposed that LCA is the endogenous ligand for PXR, inducing CYP3A gene transcription and thus providing greater capacity for hepatic bile acid detoxification (3, 11) . This conclusion has been reached on the basis of cell culture-based experiments and cell-free ligand affinity assays (38) , showing that mouse and human PXR are preferentially activated by LCA and its metabolite, 3-keto-LCA, but not by a range of conjugated bile acids (11) . LCA is a known CYP3A substrate, and activation of PXR confers resistance to LCA-induced hepatotoxicity in mice pre-treated with the potent PXR ligand pregnenolone 16α-carbonitrile. However PXR also increases transcription of a phase ΙΙ conjugating enzyme, dehydroepiandrosterone sulfotransferase, which sulfates LCA and facilitates its elimination (39) , and this mechanism, rather than CYP3A induction, may also account for some of the PXR-conferred protection from LCA toxicity.
We provide substantial evidence that CYP3A induction in both rodents and humans is an important part of the liver's adaptive response to detoxify bile acids in acute cholestasis, even when there is no increase in circulating LCA. Indeed, animals injected with supra-physiological concentrations of LCA only had pericapsular hepatic induction of the transgene, corresponding to the area of maximal exposure to this bile acid, with minimal parenchymal induction despite serum LCA concentrations sufficiently high to induce hepatic necrosis well away from pericapsular liver. Therefore the role of other bile acids as regulatory molecules must be considered. Other potential bile acid ligands for PXR in human and mouse include CDCA and DCA (3, 17) . CDCA is a relatively hydrophobic and toxic primary bile acid (40) . TCDCA is a substrate of CYP3A4 for 6α-hydroxylation in humans (7); is a substrate for β-hydroxylation in rats (29) , and increased significantly in concentration after BDL in the present study.
However, it has recently been reported that PXR function is inhibited in the presence of CDCA or CA through the up-regulation of small heterodimer partner (SHP; NR1I0) (41) , and TCDCA has also been shown to reduce CYP3A-associated monooxygenase activities in vivo in rats (42) . DCA is a secondary bile acid, and concentrations of TDCA decrease significantly after BDL. FXR also acts as a bile acid "sensor," and is activated by both the primary bile acids, CDCA and CA, and the secondary bile acids LCA, DCA, and their conjugated metabolites (38) . Although FXR has been shown to modestly activate a CYP3A4 reporter gene in the presence of CDCA and DCA, it is unlikely to be a positive regulator of CYP3a11 as FXR also increases SHP expression, and Cyp3a11 protein and mRNA can be dramatically increased in the absence of FXR (17) . UDCA and TUDCA can also activate PXR, and induce CYP3A
protein and associated testosterone 6β-hydroxylase activity in primary human hepatocytes, but have not been studied against murine PXR (17) .
In addition to PXR and FXR, other relevant members of the nuclear receptor NR1 subfamily include VDR and CAR. VDR is expressed in hepatic nonparenchymal sinusoidal cell populations and biliary cells (43) , and can be activated by LCA and its major metabolites; 3-keto-LCA, G-LCA and 6-keto-LCA, inducing expression of CYP3A at lower concentrations than those required for activation of PXR. However, these secondary bile acids were not elevated in the present study, and primary bile acids including CDCA, CA, UDCA and their conjugated metabolites are not effective ligands for VDR (16). It therefore seems unlikely that VDR mediates the CYP3A up regulation observed in the present study.
The nuclear receptor CAR is activated by some of the same ligands as PXR; regulates a subset of common genes, e.g. CYP3A and CYP2B; and can signal through the same signalling pathways (15, 44) .
CAR is less promiscuous than PXR and displays a high basal level of activity that can be reduced by the In summary, the present study has shown that adaptive up-regulation of important CYP3A genes occurs in acute cholestasis, in conjunction with an increase in hydroxylated bile acid production, as part of a co-ordinated protective response to detoxify bile acids. We have characterised changes in serum, liver and urinary bile acids in mice after BDL, and provide evidence that CYP3A induction is not dependent on increases in circulating LCA. Gaining further insights into the mechanisms by which bile acids trigger feed-forward adaptation of detoxification pathways is an important goal as it will facilitate the development of rational therapies for use in cholestatic liver disease. 
